High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease

Parkinsonism and Related Disorders

Volumn 16, Issue 8, 2010, Pages 513-516

  Schnitzler, Alfons ^a   Leffers, Karl Werner ^b   Häck, Hermann Josef ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UCB PHARMA   (Belgium)

Author keywords

Dopamine agonist; Parkinson's disease; Rotigotine; Transdermal patch; Treatment compliance

Indexed keywords

CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GAMMA GLUTAMYLTRANSFERASE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; APPLICATION SITE REACTION; ARTICLE; BALANCE DISORDER; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERHIDROSIS; IDIOPATHIC DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTLESSNESS; SHOCK; SIDE EFFECT; SKIN TOXICITY; SLEEP DISORDER; TREATMENT DURATION; TREMOR; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING;

AGED; ANTIPARKINSON AGENTS; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PATIENT COMPLIANCE; PATIENT SATISFACTION; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH;

EID: 77956180778     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.06.009     Document Type: Article

References (22)

1. Leopold N.A., Polansky M., Hurka M.R. Drug adherence in Parkinson's disease. Mov Disord 2004, 19:513-517.
2. Grosset K.A., Bone I., Grosset D.G. Suboptimal medication adherence in Parkinson's disease. Mov Disord 2005, 20:1502-1507.
3. Fargel M., Grobe B., Oesterle E., Hastedt C., Rupp M. Treatment of Parkinson's disease: a survey of patients and neurologists. Clin Drug Invest 2007, 27:207-218.
4. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
5. Grosset D., Antonini A., Canesi M., Pezzoli G., Lees A., Shaw K., et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009, 24:826-832.
6. Kornick C.A., Santiago-Palma J., Moryl N., Payne R., Obbens E.A. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003, 26:951-973.
7. Urdl W., Apter D., Alperstein A., Koll P., Schönian S., Bringer J., et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol 2005, 121:202-210.
8. Watts R.L., Jankovic J., Waters C., Rajput A., Boroojerdi B., Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276.
9. Poewe W.H., Rascol O., Quinn N., Tolosa E., Oertel W.H., Martignoni E., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-520.
10. Oertel W.H., Beneš H., García-Borreguero D., Geisler P., Högl B., Saletu B., et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008, 9:228-239.
11. Trenkwalder C., Beneš H., Poewe W., Oertel W.H., García-Borreguero D., de Weerd A.W., et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008, 7:595-604.
12. Braun M., Cawello W., Poole K., Horstmann R. Steady-state pharmacokinetics of rotigotine in patients with early-stage Parkinson's disease. Eur J Neurol 2005, 12(SSSS):37-300. (abstract P1245).
13. LeWitt P.A., Lyons K.E., Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system. PREFER Study. Neurology 2007, 68:1262-1267.
14. Setter S.M. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson's disease. Neurol Clin 2008, 26:S45-S63.
15. ® transdermal patch. Package label Available at:, [accessed 03.05.09]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/neupro/H-626-PI-en.pdf.
16. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
17. Richter A., Anton S.F., Koch P., Dennett S.L. The impact of reducing dose frequency on health outcomes. Clin Ther 2003, 25:2307-2335.
18. Cramer J.A., Mattson R.H., Prevey M.L., Scheyer R.D., Ouellette V.L. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989, 261:3273-3277.
19. Grosset D., Grosset K., Emmermann A., Hastedt C., Tischer B. Improved self-reported compliance with transdermal (patch) versus oral medication in Parkinson's disease patients. Eur J Neurol 2006, 13(Suppl. 2):88-89. (abstract P1175).
20. Poewe W. Treatments for Parkinson disease past achievements and current clinical needs. Neurology 2009, 72:S65-S73.
21. Parkinson Study Group A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003, 60:1721-1728.
22. Giladi N., Boroojerdi B., Korczyn A.D., Burn D.J., Clarke C.E., Schapira A.H.V. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404.